Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease (Q34477459)

2 August 2017

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease (English)

1 reference

Alzheimer's Disease Neuroimaging Initiative

2 August 2017

0 references

0 references

series ordinal

10

object named as

Alzheimer's Disease Neuroimaging Initiative

1 reference

2 August 2017

7

Michael C Donohue

1 reference

2 August 2017

9

Michael W Weiner

1 reference

2 August 2017

8

Paul S Aisen

1 reference

2 August 2017

2

Niklas Mattsson

1 reference

2 August 2017

4

John Kornak

1 reference

2 August 2017

5

Rachel Nosheny

1 reference

2 August 2017

1

Philip S Insel

1 reference

2 August 2017

3

R Scott Mackin

1 reference

2 August 2017

6

Duygu Tosun-Turgut

1 reference

2 August 2017

21 March 2015

1 reference

Annals of clinical and translational neurology

2 August 2017

1 reference

2 August 2017

2

1 reference

2 August 2017

534-547

1 reference

2 August 2017

5

1 reference

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

The A4 study: stopping AD before symptoms begin?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Early indications of future cognitive decline: stable versus declining controls

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

APOE modifies the association between Aβ load and cognition in cognitively normal older adults

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Report of the task force on designing clinical trials in early (predementia) AD.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

A new rating scale for Alzheimer's disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

6 July 2018

1 reference

Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain

21 January 2018

1 reference

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease

21 January 2018

1 reference

Apolipoprotein E epsilon 4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease.

21 January 2018

1 reference

Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.

21 January 2018

1 reference

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

21 January 2018

1 reference

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets

21 January 2018

1 reference

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

21 January 2018

1 reference

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.

21 January 2018

1 reference

The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435707

Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26000325

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/ACN3.192

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

PubMed ID

26000325